Novo Nordisk A/S

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Novo Nordisk A/S is $61.89. At the current market price of $42.15, NONOF trades 46.8% below its calculated fair value.

Novo Nordisk A/S is currently undervalued based on our valuation model. The stock trades at $42.15, which is 46.8% below the fair price of $61.89. The P/E ratio of 11.2x is a key metric in the valuation.

With a 20% margin of safety applied to the fair price of $61.89, the conservative entry level for NONOF is $49.51. At the current market price of $42.15, the stock trades 17.5% below this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.

We update fair price calculations for NONOF daily after market close. The current fair price of $61.89 incorporates the latest market data and sector multiples.

NONOF's fair price of $61.89 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 11.2x, ROE of 61.1%, and dividend yield of 3.65%.

At $42.15, NONOF trades 46.8% below our fair value estimate of $61.89. The stock is currently undervalued. ROE stands at 61.1% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.

NONOF has a dividend yield of 3.65%.